Morgan Stanley lowered the firm’s price target on Certara (CERT) to $12 from $16 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara price target lowered to $13 from $14 at Barclays
- Midday Fly By: Broadcom slides, pot stocks jump
- Certara backs FY25 adjusted EPS view 45c-47c, consensus 45c
- Certara price target lowered to $12 from $15 at Stephens
- Certara’s Strategic Transition: Balancing Growth Prospects with Short-term Uncertainties